1. Pink Sheet
  2. >>Vaccines

What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers

 
• By Bowman Cox

US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.

Emergent BioSolutions
what went wrong this time • Source: Alamy

More insight into what went wrong when the Emergent BioSolutions, Inc. Bayview plant in Baltimore ramped up for COVID-19 vaccine drug substance manufacturing emerged during a 19 May US congressional hearing.

And there were glimmers at the House Select Subcommittee on the Coronavirus Crisis hearing of the lessons that must be learned to prepare for the next pandemic, mostly around the challenge of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.